Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.38 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.35 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.35 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.35 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.35 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.35 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1238805 | 1.00 | SLC1A1 (0.53) | SLC1A1TSHRLMNAKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL624146 | 1.00 | SLC1A1 (0.53) | SLC1A1TSHRLMNAKDM4EKMT2A | |
| SCHEMBL1318285 | 0.98 | SLC1A1 (0.55) | SLC1A1TSHRLMNAKDM4EKMT2A | |
| SCHEMBL131050 | 0.98 | SLC1A1 (0.55) | SLC1A1TSHRLMNAKDM4EKMT2A | |
| SCHEMBL131049 | 0.98 | SLC1A1 (0.55) | SLC1A1TSHRLMNAKDM4EKMT2A | |
| SCHEMBL28180863 | 0.96 | SLC1A1 (0.53) | SLC1A1TSHRLMNAKDM4EKMT2A | |
| SCHEMBL20474981 | 0.89 | SLC1A1 (0.47) | SLC1A1TSHRLMNAKDM4EKMT2A | |
| SCHEMBL10633361 | 0.89 | SLC1A1 (0.47) | SLC1A1TSHRLMNAKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL7163088 | 0.88 | TSHR (0.52) | SLC1A1TSHRLMNAKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL28514709 | 0.88 | TSHR (0.52) | SLC1A1TSHRLMNAKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119409588-A | Caffeoyl amino acid methyl ester derivative and preparation method and application thereof | 西北大学 | 2025-02-11 | — | — | CN | claimed |
| CN-119351754-A | Recycling treatment method of copper-containing sludge | 江西省金瑞环保科技有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-119241617-A | 2 '-Deoxy-2' -fluoro-N4-substituted cytidine compound, preparation method and application thereof | 河南省科学院高新技术研究中心 | 2025-01-03 | — | — | CN | claimed |
| CN-119144151-A | Preparation of hydrogels and uses thereof | 粤港澳大湾区精准医学研究院(广州) | 2024-12-17 | — | — | CN | claimed |
| CN-117946007-A | Curcumin-amino acid methyl ester derivative and preparation method and application thereof | 河北科技大学 | 2024-04-30 | — | — | CN | claimed |
| CN-117903078-A | Amide derivative containing 3, 4-dichloro isothiazole, preparation method and application thereof | 南开大学 | 2024-04-19 | — | — | CN | claimed |
| CN-113912524-B | Polypeptide compound containing sulfur amide and synthesis method thereof | 华东师范大学 | 2023-12-01 | — | — | CN | claimed |
| CN-115819652-B | 2-aminopentanedioxime acid modified polyacrylic acid chelate resin and preparation method and application thereof | 中南大学 | 2023-09-05 | — | — | CN | claimed |
| CN-115947670-A | Synthesis process of N-tert-butyloxycarbonyl-L-glutamic acid dimethyl ester | 常州吉恩药业有限公司 | 2023-04-11 | — | — | CN | claimed |
| CN-115819652-A | 2-amino pentanedioxyhydroxamic acid modified polyacrylic acid chelating resin and preparation method and application thereof | 中南大学 | 2023-03-21 | — | — | CN | claimed |
| CN-113527399-A | Ginsenoside CK derivative and application thereof in preparation of antitumor drugs | 陕西巨子生物技术有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-111807994-A | L-glutamic acid derivative and synthesis method and application thereof | 四川嘉瑛莱科技有限责任公司 | 2020-10-23 | — | — | CN | claimed |
| CN-111574973-A | Three-water-retention-based drilling fluid system | 石家庄华莱鼎盛科技有限公司 | 2020-08-25 | — | — | CN | claimed |
| US-20130165654-A1 | PROCESSES FOR PREPARING PEMETREXED | DR. REDDY'S LABORATORIES, INC. (US) | 2013-06-27 | — | — | US | claimed |
| CN-101928321-B | Acidic amino acid chemically-modified ursolic acid derivatives with anti-cancer activities | UNIV FUZHOU | 2012-09-05 | — | — | CN | claimed |
| EP-2464650-A2 | PROCESSES FOR PREPARING PEMETREXED | Dr. Reddy's Laboratories, Ltd. (IN) | 2012-06-20 | — | — | EP | claimed |
| CN-101333173-B | N-[4-(butanal-4-group)-benzoyl]-L-glutamic acid dimethyl ester compound and method for preparing pemetrexed by using the compounds | QILU PHARMACEUTICAL CO LTD | 2011-08-10 | — | — | CN | claimed |
| WO-2011019986-A2 | PROCESSES FOR PREPARING PEMETREXED | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-02-17 | — | — | WO | claimed |
| CN-101928321-A | Acidic amino acid chemically-modified ursolic acid derivatives with anti-cancer activities | UNIV FUZHOU | 2010-12-29 | — | — | CN | claimed |
| CN-101333173-A | N-[4-(butanal-4-group)-benzoyl]-L-glutamic acid dimethyl ester compound and method for preparing pemetrexed by using the compounds | QILU PHARMACEUTICAL CO LTD (CN) | 2008-12-31 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165654-A1 | PROCESSES FOR PREPARING PEMETREXED | TYMP, TYMS, DPYD | CA2 4647/4885GRIN2D 3971/4885GRIN3B 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.